Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

344
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
344
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

235
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
235
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

1.3K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.3K
Cancer Therapies02:49

Cancer Therapies

10.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

205
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
205
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

374
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
374

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Envudeucitinib, a Potent, Next-Generation, Allosteric Inhibitor of TYK2: A Narrative Review.

Dermatology and therapy·2026
Same author

Brodalumab's 8-Year Journey in Plaque Psoriasis: Insights into Efficacy, Safety, and Real-World Evidence.

Journal of drugs in dermatology : JDD·2026
Same author

Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitors.

Journal of the American Academy of Dermatology·2025
Same author

Establishing consensus on defining failure of topical therapy in psoriasis: Recommendations from the International Psoriasis Council.

Journal of the American Academy of Dermatology·2025
Same author

Systemic Corticosteroid Use in Atopic Dermatitis: A Position Paper to Inform Safer Clinical Practice and Policy.

The Journal of investigative dermatology·2025
Same author

Two-Year Treatment Persistence of Guselkumab vs Other Biologics in Plaque Psoriasis Patients.

Journal of drugs in dermatology : JDD·2025

Related Experiment Video

Updated: Mar 16, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.7K

Why Biologic Therapies Sometimes Lose Efficacy.

Bruce E Strober1

  • 1Professor and Chair Department of Dermatology University of Connecticut Health Center Farmington, Connecticut.

Seminars in Cutaneous Medicine and Surgery
|August 16, 2016
PubMed
Summary

Biologic therapies for psoriasis can lose effectiveness over time. Using an immunomodulatory agent may reduce antibody formation and improve treatment outcomes for psoriasis patients.

Keywords:
Anti-drug antibodiesbiologics;immunogenicity;loss of responsepsoriasisserum drug levels

More Related Videos

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K
Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

671

Related Experiment Videos

Last Updated: Mar 16, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.7K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K
Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

671

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Biologic therapies are crucial for managing psoriasis.
  • Loss of response to biologics over time is a significant clinical challenge.
  • Factors contributing to loss of response include immunogenicity and suboptimal drug levels.

Purpose of the Study:

  • To explore strategies for maintaining the long-term efficacy of biologic therapies for psoriasis.
  • To investigate the role of immunomodulatory agents in mitigating loss of response.

Main Methods:

  • Review of existing literature on biologic therapy for psoriasis.
  • Analysis of factors contributing to loss of response, including immunogenicity.
  • Evaluation of the potential benefits of co-administered immunomodulatory agents.

Main Results:

  • Loss of response to psoriasis biologics is multifactorial.
  • Immunogenicity, characterized by anti-drug antibody formation, is a key driver of treatment failure.
  • Suboptimal dosing and intermittent therapy also contribute to reduced effectiveness.

Conclusions:

  • Immunogenicity is a primary reason for the loss of response to biologic therapies in psoriasis.
  • Co-administration of an immunomodulatory agent can potentially decrease immunogenicity.
  • Strategies to manage immunogenicity may improve long-term clinical response to psoriasis biologics.